Skip to main content

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Completed · Phase 3 · NCT03661320

Conditions: Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer

At a glance

Research payments reported, 2025
$65,215
U.S. investigators named
7
Sites paid
7
Planned or actual enrollment
855

About the trial

Sponsor
Bristol-Myers Squibb (with Ono Pharmaceutical Co., Ltd.)
Tested
Nivolumab (biological), Gemcitabine (drug), Cisplatin (drug)
Dates
Started 2018-11-06; completion 2026-04-14
Results posted
Not yet

The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).

From ClinicalTrials.gov, last updated 2026-09-10. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $65,215 in research payments for this study in 2025 (13 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Virginia Oncology Associates $26,555
  • Northwest Cancer Specialists, PC $14,130
  • Rocky Mountain Cancer Centers LLP $8,055
  • Minnesota Hematology / Oncology, PA $6,555
  • Texas Onco Southwest Fort Worth $5,055
  • Maryland Oncology Hematology, PA $3,930
  • Woodlands Medical Specialists, PA $935

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.